Research Paper Volume 12, Issue 20 pp 20835—20861

SMARCD3 is a potential prognostic marker and therapeutic target in CAFs

Figure 7. SMARCD3 expression is positively correlated with metastasis, TGF-β pathway activation and Mesenchymal signatures.